Recall
FDAHealthJune 22, 2026

Direct Rx — DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.

⚠️ CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
June 22, 2026

U.S. Nationwide

What's affected?

Product
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.
Lot code
a)

Additional details

Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 263 Bottles.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.